Federal Register / Vol. 74, No. 167 / Monday, August 31, 2009 / Notices 44861 

Date: September 24, 2009. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Ellen K. Schwartz, EDD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3150, 

MSC 7770, Bethesda, MD 20892, 301–435– 

0681, schwarte@csr.nih.gov. 

Name of Committee: Bioengineering 

Sciences & Technologies Integrated Review 

Group Biomaterials and Biointerfaces Study 

Section. 

Date: September 30–October 1, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hilton Alexandria Old Town, 1767 

King Street, Alexandria, VA 22314. 

Contact Person: Steven J. Zullo, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5146, 

MSC 7849, Bethesda, MD 20892, 301–435– 

2810, zullost@csr.nih.gov. 

Name of Committee: Bioengineering 

Sciences & Technologies Integrated Review 

Group Nanotechnology Study Section. 

Date: September 30–October 1, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Westin Annapolis Hotel, 100 

Westgate Circle, Annapolis, MD 21401. 

Contact Person: Joseph D. Mosca, PhD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5158, 

MSC 7808, Bethesda, MD 20892, (301) 435– 

2344, moscajos@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: August 24, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–20876 Filed 8–28–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the Board 

of Scientific Counselors, National 

Institute of Neurological Disorders and 

Stroke. The meeting will be closed to 

the public as indicated below in 

accordance with the provisions set forth 

in section 552b(c)(6), Title 5 U.S.C., as 

amended for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Institute of Neurological 

Disorders and Stroke, including 

consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, National Institute of 

Neurological Disorders and Stroke. 

Date: October 4–6, 2009. 

Time: 7 p.m. to 12:30 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Alan P. Koretsky, PhD, 

Scientific Director, Division of Intramural 

Research, National Institute of Neurological 

Disorders & Stroke, NIH, 35 Convent Drive, 

Room 6A 908, Bethesda, MD 20892, 301– 

435–2232, koretskya@ninds.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: August 24, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–20874 Filed 8–28–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

Services Subcommittee of the 

Interagency Autism Coordinating 

Committee (IACC). 

The purpose of the Services 

Subcommittee is to review the current 

state of services and supports for 

individuals with Autism Spectrum 

Disorder (ASD) and their families in 

order to improve these services. The 

meeting will be open to the public with 

attendance limited to space available. 

The meeting will also be open to the 

public through a conference call phone 

number and a Web presentation tool on 

the Internet. Individuals who participate 

in person or by using electronic services 

and who need special assistance, such 

as captioning of the conference call or 

other reasonable accommodations, 

should submit a request to the Contact 

Person at least 7 days prior to the 

meeting. 

Name of Committee: Interagency Autism 

Coordinating Committee (IACC). 

Type of meeting: Services Subcommittee. 

Date: September 15, 2009. 

Time: 1 p.m. to 4 p.m. Eastern Time. 

Agenda: Discussion of the IACC Services 

Town Hall Meeting that took place on July 

24, 2009 in St. Charles, IL, and a presentation 

by IACC Services Subcommittee member Dr. 

Gail Houle and Dr. Sam Odom about 

programs for children with autism supported 

by the Department of Education. 

Place: 

In Person: National Institutes of Health, 

Main Campus Building 1, Wilson Hall, 3rd 

Floor, 1 Center Drive, Bethesda, MD 20892. 

Webinar: https://www2.gotomeeting.com/ 

register/724090747. To Access the 

Conference Call: Dial: 888–455–2920. Access 

code: 5697907. 

Contact Person: Ms. Lina Perez, Office of 

Autism Research Coordination, Office of the 

Director, National Institute of Mental Health, 

NIH, 6001 Executive Boulevard, NSC, Room 

8200, Bethesda, MD 20892–9669. 301–443– 

6040. IACCPublicInquiries@mail.nih.gov. 

Please Note: Members of the public who 

participate using the conference call phone 

number will be able to listen to the meeting 

but will not be heard. For those who use the 

Web presentation tool to view the 

presentation, please call GoToWebinar at 

(800) 263–6317 to report any technical 

difficulties. 

To access the Web presentation tool 

on the Internet the following computer 

capabilities are required: 

(A) Internet Explorer 5.0 or later, 

Netscape Navigator 6.0 or later or 

Mozilla Firefox 1.0 or later; 

(B) Windows® 2000, XP Home, XP 

Pro, 2003 Server or Vista; 

(C) Stable 56k, cable modem, ISDN, 

DSL or better Internet connection; 

(D) Minimum of Pentium 400 with 

256 MB of RAM (Recommended); 

(E) Java Virtual Machine enabled 

(Recommended). 

NIH has instituted stringent security 

procedures for entrance onto the NIH 

campus. All visitors must enter through 

the NIH Gateway Center. This center 

combines visitor parking, noncommercial vehicle inspection and 

visitor ID processing, all in one location. 

The NIH will process all visitors in 

vehicles or as pedestrians. You will be 

asked to submit to a vehicle or personal 

inspection and will be asked to state the 

purpose of your visit. Visitors over 15 

years of age must provide a form of 

government-issued ID such as a driver’s 


cprice-sewell on DSK2BSOYB1PROD with NOTICES
44862 Federal Register / Vol. 74, No. 167 / Monday, August 31, 2009 / Notices 

license or passport. All visitors should 

be prepared to have their personal 

belongings inspected and to go through 

metal detection inspection. 

When driving to NIH, plan some extra 

time to get through the security 

checkpoints at the visitor entrances to 

campus. Be aware that visitor parking 

lots on the NIH campus can fill up 

quickly. The NIH campus is also 

accessible via the metro Red Line, 

Medical Center Station. The Natcher 

Conference Center is a 5-minute walk 

from the Medical Center Metro Station. 

Additional NIH campus visitor 

information is available at: http:// 

www.nih.gov/about/visitor/index.htm. 

Information about the IACC and a 

registration link for this meeting are 

available on the Web site: http:// 

www.iacc.hhs.gov. 

Dated: August 24, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–20872 Filed 8–28–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Request for Nominations to the 

SAMHSA National Advisory Council 

The Substance Abuse and Mental 

Health Services Administration 

(SAMHSA) is accepting nominations 

through October 7, 2009, to fill 

vacancies for its five advisory 

committees (the SAMHSA National 

Advisory Council, the Center for 

Substance abuse Prevention, Center for 

Substance Abuse Treatment and Center 

for Mental Health Services National 

Advisory Councils and the Advisory 

Committee for Women’s Services). 

Under section 502 of the Public Health 

Service Act, the National Advisory 

Councils (NAC) provide advice to the 

Secretary of the U.S. Department of 

Health and Human Services (HHS), 

SAMHSA Administrator, and/or Center 

Directors on a broad range of polices 

and services related to substance use 

and mental health. 

Legislation requires that each NAC be 

composed of 12 members: nine 

members must be leading 

representatives of the health disciplines 

(including public health, behavioral 

health, and social sciences) relevant to 

the mission of SAMHSA and its Centers 

and three members must be from the 

general public and include leaders in 

the fields of public policy, public 

relations, law, health policy, economics, 

or management. 

Under section 501 of the Public 

Health Service Act, the Advisory 

Committee for Women’s Services 

(ACWS) is statutorily mandated to 

advise the SAMHSA Administrator and 

the Associate Administrator for 

Women’s Services on appropriate 

activities to be undertaken by SAMHSA 

and its Centers with respect to women’s 

substance abuse and mental health 

services. The SAMHSA Administrator 

will appoint the 10 members of this 

Committee. The members must be from 

among physicians, practitioners, 

treatment providers, and other health 

professionals, whose clinical practice, 

specialization, or professional expertise 

includes a significant focus on women’s 

substance abuse and mental health 

conditions. 

The current lists of members for the 

advisory committees are available on 

the SAMHSA Web site at https:// 

nac.samhsa.gov/index.aspx. 

Members are appointed for a term of 

up to four years. Individuals are 

nominated, selected, and appointed to a 

NAC or the ACWS to contribute to the 

advisory committee’s objectives based 

on their qualifications. The Federal 

Advisory Committee Act (FACA) and 

HHS policy require that committee 

membership be fairly balanced in terms 

of points of view represented and the 

committee’s functions to be performed. 

Consideration is given to a broad 

representation of geographic areas, 

gender, race/ethnicity, and disability. 

The advisory committees will meet not 

less than two times per year and on an 

as needed basis. 

Any interested person or organization 

may nominate qualified individuals for 

membership. Self-nominations are also 

welcome. Nominations must include a 

resume and short biography describing 

the educational and professional 

qualifications of the nominee and the 

nominee’s current occupation, position, 

address and daytime telephone number. 

Individuals may be recommended for 

membership on more than one advisory 

committee, but will be appointed to 

only one advisory body. Nominations 

can be sent by U.S. Mail or 

electronically to Ms. Toian Vaughn, 

Designated Federal Official, at the 

address below. 

Contact: Toian Vaughn, M.S.W., 

Designated Federal Official, SAMHSA 

National Advisory Council and 

SAMHSA Committee Management 

Officer, 1 Choke Cherry Road, Room 8– 

1089, Rockville, Maryland 20857. 

Telephone: (240) 276–2307; Fax: (240) 

276–2220 and E-mail: 

toian.vaughn@samhsa.hhs.gov. 

Toian Vaughn, 

Committee Management Officer, Substance 

Abuse and Mental Health Services 

Administration. 

[FR Doc. E9–20884 Filed 8–28–09; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Development of AntiAngiogenesis Cancer Therapeutics 

Targeting Adrenomedullin or 

Proadrenomedullin N-Terminal 20 

Peptide (PAMP) 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

404.7(a)(1)(i), that the National 

Institutes of Health (NIH), Department 

of Health and Human Services, is 

contemplating the grant of an exclusive 

patent license to practice the inventions 

embodied in U.S. Patent Application 

No. 60/002,514, filed on August 18, 

1995, entitled ‘‘Functional Role of 

Adrenomedullin (AM) and the GeneRelated Product (PAMP) in Human 

Pathology and Physiology’’ (HHS 

Reference No. E–206–1995/0–US–01); 

U.S. Patent Application No. 60/002,936, 

filed on August 30, 1995, entitled 

‘‘Functional Role of Adrenomedullin 

(AM) and the Gene-Related Product 

(PAMP) in Human Pathology and 

Physiology’’ (HHS Reference No. E– 

206–1995/1–US–01); U.S. Patent 

Application No. 60/013,172, filed on 

March 12, 1996, entitled ‘‘Functional 

Role of Adrenomedullin (AM) and the 

Gene-Related Product (PAMP) in 

Human Pathology and Physiology’’ 

(HHS Reference No. E–206–1995/2–US– 

01); PCT Application No. PCT/US96/ 

13286, filed on August 16, 1996, 

entitled ‘‘Functional Role of 

Adrenomedullin (AM) and the GeneRelated Product (PAMP) in Human 

Pathology and Physiology’’ (HHS 

Reference No. E–206–1995/3–PCT–01); 

Australian Patent No. 710662, issued on 

October 5, 2000, entitled ‘‘Functional 

Role of Adrenomedullin (AM) and the 

Gene-Related Product (PAMP) in 

Human Pathology and Physiology’’ 

(HHS Reference No. E–206–1995/3–AU– 

02); Canadian Patent Application No. 

2229741, filed on August 16, 1996, 

entitled ‘‘Functional Role of 


cprice-sewell on DSK2BSOYB1PROD with NOTICES